Specifically, we considered lymph node metastases, age, number of total non-silent mutations, number of CpGT mutations, BRAF-RAF score, ERK score, miRNA cluster, RPPA cluster, ploidy, differentiation score, and follicular component. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.